Skip to Content Skip to Search

GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine

GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs since the start of the H1N1 pandemic. We recognise that pandemics are unpredictable and that government needs and plans have evolved as understanding of the H1N1 pandemic has increased. We are committed to working with them to respond their needs as the pandemic evolves and find appropriate and fair solutions.

Issued: London UK

GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs since the start of the H1N1 pandemic. We recognise that pandemics are unpredictable and that government needs and plans have evolved as understanding of the H1N1 pandemic has increased. We are committed to working with them to respond their needs as the pandemic evolves and find appropriate and fair solutions.

Today, GlaxoSmithKline KK (GSK) in Japan confirmed that it has reached an agreement with the Government of Japan (Ministry of Health, Labour and Welfare) to amend its existing contract to receive approximately 68 per cent of the ordered vaccine.

The Company is currently in ongoing discussions with a number of governments worldwide regarding their specific pandemic planning needs, including governments who are changing their planned immunization programs.

Pandemics by their nature are unpredictable and we recognize that governments’ needs are changing. We are committed to finding fair solutions for governments changing their immunization programs.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Enquiries:

UK Media enquiries:

Philip Thomson

(020) 8047 5502

Claire Brough

(020) 8047 5502

Stephen Rea

(020) 8047 5502

Alexandra Harrison

(020) 8047 5502

Jo Revill

(020) 8047 5502

US Media enquiries:

Nancy Pekarek

(919) 483 2839

Mary Anne Rhyne

(919) 483 2839

Kevin Colgan

(919) 483 2839

Sarah Alspach

(919) 483 2839

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

Jen Hill Baxter

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS